News

The venture capital financing was led by Vivo Ventures with additional funding from Palo Alto Investors, and private investors. The financing will support the ongoing clinical development program

The approval will allow Akorn to effectively compete in a market estimated to be worth $225 million in the US. In March 2007, Akorn announced that it had

The HeartLife Tempo Card uses the amplification technology contained in Signalife’s Fidelity 100 Heart Monitor and will be capable of storing up to six, 45-second recordings. With the

Under the terms of the agreement, Beijing Med-Pharm is responsible for attaining SFDA approval of Enablex, a process that is expected to last through 2010. Once approved, Beijing

Subject to customary closing conditions, the acquisition is expected to close in January 2008. China Medical Technologies expects the acquisition to be accretive from the quarter ending March

This initial clinical trial is designed to compare the efficacy and safety of four different dosage strengths of Q8003IR versus placebo in a post-surgery, acute pain setting. The

A total of 83 patents worldwide have been issued relating to ISA247’s structure, composition, formulation and methods of synthesis. ISA247 is currently being investigated in a Phase IIb

The data obtained during the investigation indicates that tgAAC94 did not contribute to the patient’s death, which was due to disseminated histoplasmosis. Final molecular test results also supported

The company, which had approximately 58.1 million shares of common stock outstanding as of September 30, 2007, is not obligated to repurchase any specific number of shares under